KMT2A and leukemia: - inhibition of CK2 with a Ki of 40 nM- high selectivity towards CK2 confirmed using serine/threonine (ASK1, JNK3, Aurora A, and Rock 1) and tyrosine protein kinases (FGFR1, Met, and Tie2)- inhibition of CK2 decreases taspase1-dependent MLL1 processing leading to higher MLL1 stability, and finally displace the MLL chimeras from chromatin- suppression of CK2 retard the leukemic progression in a MLL-AF9 leukemia mouse model